Impact Factor 3.9 | CiteScore 4.3
More on impact ›
In the Gene and Cell Therapy section of Frontiers in Medicine, we welcome submissions of both original research and reviews on the latest innovative therapies, including and not limited to, gene and stem cell therapies.
Over the past decade, gene therapy has enabled curative outcomes in previously untreatable genetic diseases such as X-linked severe combined immunodeficiency. Recent developments in genome-editing technology are likely to further enable the ex vivo editing of autologous hematopoietic stem/progenitor cells (HSPCs) for clinical benefit of patients. With advances come also additional challenges not only from a basic science perspective but also challenges in translating the scientific advances to the clinic, including social, ethical, economic, as well as overall public health issues.
In the Gene and Cell Therapy section of Frontiers in Medicine, we welcome submissions of both original research and reviews on the latest innovative therapies, including and not limited to, gene and stem cell therapies. The full range of issues that enable successful translation and implementation of innovative therapies are covered in this section, including basic scientific discoveries; challenges faced in translation to large-scale use, including bioengineering and bioprocessing considerations; regulatory, ethical and health economic issues; as well as any public health challenges.
Indexed in: PubMed, PubMed Central (PMC), Scopus, Google Scholar, DOAJ, CLOCKSS
PMCID: all published articles receive a PMCID
Gene and Cell Therapy welcomes submissions of the following article types: Brief Research Report, Case Report, Clinical Trial, Correction, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Study Protocol, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Gene and Cell Therapy, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact email@example.com
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact firstname.lastname@example.org